Vitamin A Level of 13.5 µg/dL: Interpretation and Management
A serum retinol level of 13.5 µg/dL (0.47 µmol/L) indicates vitamin A deficiency and requires supplementation with oral or intramuscular vitamin A preparations. This value falls well below the deficiency threshold of <0.7 µmol/L (<20 µg/dL) established by international guidelines 1, 2.
Clinical Significance
Your patient's level represents severe subclinical vitamin A deficiency. Using the conversion factor provided in the ESPEN guidelines (1 mg/dL = 0.0357 mmol/L), 13.5 µg/dL equals approximately 0.47 µmol/L 1. This is concerning because:
- Values <0.7 µmol/L indicate deficiency when present in ≥15% of a population 2
- Individual levels this low suggest depleted liver stores
- Clinical manifestations may already be present or imminent
Important Caveats Before Treatment
Check for inflammation first - serum retinol concentrations decrease with inflammation and may not reflect true vitamin A status 1. Measure:
- C-reactive protein (CRP)
- Alpha-1-acid glycoprotein (AGP)
If either marker is elevated, the retinol level may be falsely low due to:
- Reduced RBP release from the liver during inflammation
- Redistribution of the prealbumin-RBP complex from plasma 1
The BRINDA adjustment tool can correct for inflammation effects, though this is primarily used in population studies 1.
Identify the Underlying Cause
Actively search for conditions causing vitamin A deficiency 1:
High-risk conditions:
- Liver disease - prevalence increases with disease severity; 69.8% of liver transplant candidates are deficient 1
- Chronic alcohol consumption - depletes liver stores even when serum levels appear normal 1
- Malabsorption syndromes: short bowel syndrome, cystic fibrosis, celiac disease, chronic diarrhea 1
- Chronic kidney disease - paradoxically may show high levels initially, but can progress to deficiency; requires regular monitoring 1
Clinical Manifestations to Assess
Early signs (likely present at this level):
- Increased susceptibility to respiratory infections 1
- Impaired intestinal immune and barrier function 1
Progressive ocular signs (assess urgently):
- Night blindness (insufficient rhodopsin synthesis)
- Bitot spots (grey/white foamy appearance on conjunctiva)
- Xerophthalmia
- Keratomalacia (worst case - leads to blindness) 1
Treatment Approach
For mild to moderate deficiency at this level, use oral or intramuscular vitamin A preparations as outlined in the ESPEN guideline Table 12 1. The guideline states "mild deficiency can also be treated with the doses proposed" but notes that for very low serum retinol levels, IV retinol palmitate has been proposed, though data are insufficient for formal recommendation 1.
Critical treatment considerations:
- Women of childbearing age: Exercise extreme caution - retinoids are teratogenic 1. The upper limit is 3000 mg/d (10,000 IU) 1
- Avoid over-supplementation: Chronic toxicity occurs with >25,000 IU daily for >6 years or >100,000 IU for >6 months 1
- Monitor response: Recheck serum retinol after treatment initiation
Special Populations
Do NOT supplement in chronic kidney disease without careful monitoring - these patients often show falsely elevated retinol levels that can mask true deficiency 1.
For parenteral nutrition patients: Use light-protecting materials during administration as vitamin A is photosensitive and can adsorb to infusion bags 1.
Monitoring Strategy
Given the limitations of serum retinol (homeostatically controlled until liver stores are dangerously low 3, 4, 5), consider:
- Retinyl esters measurement if available - levels >250 nmol/L suggest hypervitaminosis 1
- Regular follow-up retinol measurements after supplementation
- Clinical assessment for resolution of symptoms
The key pitfall: Serum retinol has high specificity but questionable sensitivity compared to liver stores 3. A low value like 13.5 µg/dL is highly specific for deficiency, but normal values don't exclude it 3, 5.